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Group B streptococcus (GBS) neonatal sepsis is a serious disease causing newborn mortality and long-
term neurologic sequelae. The Centers for Disease Control and Prevention (CDC) recommend third-
trimester GBS screening and intrapartum antibiotic prophylaxis for high-risk women. The aim of our study
was to identify colonized pregnant women and assess the prevalence of GBS in pregnancy and the
susceptibility pattern of GBS in southern Taiwan. We performed the study at the Department of Obstetrics
and Gynecology, Kaohsiung Women and Children’s Hospital, between January and December 2002. Distal
vaginal and anorectal swabs were obtained from pregnant women at 35 or more weeks’ gestation. Swabs
were used to inoculate selected medium, which was subcultured onto sheep’s blood agar after 24 hours.
Sensitivity to azithromycin, clindamycin, erythromycin, ofloxacin, penicillin G, tetracycline, trimethoprim/
sulfamethoxazole, and vancomycin was tested using the disc diffusion method. Of the 374 pregnant women
enrolled in the study, 56 (15%) had positive cultures for GBS. Antibiotic susceptibility was as follows:
azithromycin 44.6%, clindamycin 66.1%, erythromycin 70.5%, ofloxacin 70.5%, penicillin G 60.7%,
tetracycline 39.3%, trimethoprim/sulfamethoxazole 35.7%, and vancomycin 100%. The CDC recommend
penicillin as the first choice for intrapartum prophylaxis, with erythromycin and clindamycin as alternatives
for penicillin-allergic patients. There has been increasing resistance to these antibiotics among GBS. Third-
trimester GBS screening and susceptibility testing for pregnant women should be considered.
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Group B streptococcus (GBS) was first described as a human
pathogen 60 years ago [1] and recognized as a major cause
of neonatal sepsis in the 1970s [2]. GBS is the major infectious
cause of illness and death in the newborn population. It is
also a leading cause of early neonatal sepsis [3] and may
cause chorioamnionitis, sepsis, and urinary tract infection
during pregnancy [4,5]. Approximately 80% of GBS disease
in newborns occurs during the first week of life and is re-
ferred to as early-onset disease to differentiate it from late-
onset disease, which occurs after the first week of life [5].
Early-onset GBS disease is caused by the transmission of
GBS from the mother, who carries GBS in her genital tract or
anorectum, to the newborn during delivery or in utero just
prior to delivery. Intrapartum penicillin administration to
all women during labor and delivery is an effective way to
reduce the risk of early-onset GBS infection [6]. However,
there are contraindications to giving all women antibio-
tics during labor. Some methods have been developed to
identify mothers at high risk of having a child with GBS di-
sease. The emergence of strains of GBS resistant to com-
monly used antibiotics has caused great concern. The aim of
our study was to determine the prevalence and antibiotic
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sensitivity of rectovaginal GBS in pregnant women in the
third trimester.
MATERIALS AND METHODS
We carried out a prospective observational study of sus-
ceptibilities of GBS from rectovaginal cultures between
January and December 2002. Distal vaginal and anorectal
swabs were obtained when pregnant women were at 35 or
more weeks of gestation. Cases were collected from the
prenatal care unit of Kaohsiung Women and Children’s
Hospital. Swabs were used to inoculate Todd-Hewitt broth
supplemented with colistin (10 g/mL) and nalidixic acid
(15 g/mL), which was then incubated for 24 hours. The
broth was then subcultured onto a Muller-Hinton agar
plate with 5% sheep’s blood and incubated for 24 to 48
hours. GBS was identified by β-hemolytic, Gram-positive,
and catalase-negative characteristics. All GBS isolated
were tested for susceptibility to azithromycin, clindamy-
cin, erythromycin, ofloxacin, penicillin G, tetracycline,
trimethoprim/sulfamethoxazole, and vancomycin using
the disc diffusion method. Minimal inhibitory concentra-
tion breakpoints for penicillin G were 0.12 µg/mL or less
for sensitivity and at least 2.0 µg/mL for resistance. Strepto-
coccus pneumoniae was used as the control, and sensitivity
tests were conducted according to the National Com-
mittee for Clinical Laboratory Standards guidelines. Data
were analyzed using descriptive statistics.
RESULTS
Of the 374 pregnant women who had samples taken from
the distal vagina and anorectum for GBS screening, 56
(15%) had positive cultures. All isolates were sensitive to
vancomycin, while 60% were sensitive to penicillin G, the
antibiotic recommended by the Centers for Disease Control
and Prevention (CDC) as the first-choice treatment. Only
35% and 40% of samples were sensitive to tetracycline and
trimethoprim/sulfamethoxazole, respectively (Table). None
of the neonates delivered by carrier mothers developed
neonatal streptococcal sepsis.
DISCUSSION
Since the 1970s, in many industrialized countries, GBS has
been the principal cause of sepsis and meningitis during the
first week of life (i.e. early-onset disease). GBS also causes
late-onset infections (> 7 days of age but rarely after the
third month) [7]. The incidence of neonatal sepsis and
meningitis due to GBS is 0.5 to 3 cases per 1,000 live births
[8,9]. Several organizations, including the CDC [6], American
College of Obstetricians and Gynecologists [10], and the
American Academy of Pediatrics [11], have suggested that
health care providers caring for pregnant women should
implement a strategy for GBS prevention. The CDC
recommends intravenous antibiotics during labor, until
delivery. Although ampicillin is an acceptable alternative,
the narrow spectrum of penicillin G is preferred [12]. We
used a screening approach, obtaining vaginal and anorectal
cultures from women at 35 to 37 weeks’ gestation. GBS
colonization is associated with neonatal sepsis, which leads
to neonatal mortality and neurologic sequelae for survivors.
The CDC recommends intrapartum prophylaxis with
antibiotics for high-risk pregnant women. Intravenous or
intramuscular injection of antibiotics after the onset of labor
or rupture of the membranes is highly effective in reducing
neonatal colonization with GBS [13]. Several clinical trials
have demonstrated the efficacy of intrapartum antibiotic
prophylaxis in colonized women against laboratory-
Table. Antibiogram of rectovaginal group B streptococcus isolates (N = 56)
Antibiotic Sensitive, n (%) Intermediate, n (%) Resistant, n (%)
Vancomycin 56 (100.0) 0 (0) 0 (0)
Ofloxacin 42 (75.0) 9 (16.1) 5 (8.9)
Erythromycin 42 (75.0) 3 (5.4) 11 (19.6)
Penicillin G 34 (60.7) 0 (0) 22 (39.3)
Clindamycin 37 (66.1) 5 (8.9) 14 (25.0)
Azithromycin 25 (44.6) 11 (19.6) 20 (35.7)
Tetracycline 22 (39.3) 3 (5.4) 31 (55.4)
Trimethoprim/sulfamethoxazole 20 (35.7) 5 (8.9) 31 (55.4)
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confirmed, early-onset GBS disease [6]. If maternal GBS is
untreated in labor, the rate of invasive neonatal disease is
4% [10].
Samples taken from both the lower genital tract and the
rectum increase detection rates by 10% to 15% over rates
from either site alone [14]. Almost half of women colonized
with vaginal GBS at the time of delivery have negative
antenatal cultures in the third trimester [14]. The maximum
predictive value of cultures is achieved 1 to 5 weeks before
delivery; within this interval, the positive predictive value
of vaginal and rectal cultures is 87%, and the negative
predictive value is 96% [15]. Hence, we took rectovaginal
samples at 35 to 37 weeks’ gestation to improve the cor-
relation between the status at the time of culture and the
time of delivery.
A recent paper has proposed two strategies to decrease
newborn GBS disease. The first strategy, including prenatal
cultures for GBS at 35 to 37 weeks’ gestation, would prevent
86% of early-onset GBS disease. The second strategy, with-
out prenatal cultures but according to the presence of
intrapartum risk factors to determine which women should
receive intrapartum antibiotics, would prevent 69% of early-
onset GBS disease [6].
Our study revealed that 15% of our pregnant patients
were colonized with GBS in the vagina and anorectum.
These findings are similar to other published GBS
colonization rates during pregnancy of between 10% and
30% [16,17]. Specimen preparation using appropriate
incubation and culture techniques affects the sensitivity
and specificity of the results. All isolates were susceptible to
vancomycin. When a patient is allergic to penicillin, the
choices recommended by the CDC are erythromycin and
clindamycin. Like other authors, we found that resistance
to erythromycin and clindamycin was increasing among
GBS [18], so it would be useful to test for antibiotic sensiti-
vity, especially for penicillin-allergic women. Due to anti-
biotic abuse in the past, there has been an increase in re-
sistant strains of microorganisms, which causes great
concern about the restriction of antibiotics.
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